Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160688 | 0.87 | CA12 (0.53) | CA1CA2CA12CA9CYP2D6 | |
| SCHEMBL3161624 | 0.86 | CA12 (0.49) | CA1CA2CA12CA9CYP2D6 | |
| SCHEMBL17959004 | 0.86 | CA12 (0.49) | CA1CA2CA12CA9CYP2D6 | |
| SCHEMBL3150744 | 0.86 | CA12 (0.49) | CA1CA2CA12CA9GAA | |
| SCHEMBL3020849 | 0.86 | CA12 (0.51) | CA1CA2CA12CA9CYP2D6 | |
| SCHEMBL3198347 | 0.85 | CA12 (0.51) | CA1CA2CA12CA9CYP2D6 | |
| SCHEMBL3166123 | 0.84 | MAPT (0.49) | CA1CA2CA12CA9GAA | |
| SCHEMBL5201135 | 0.84 | MAPT (0.49) | CA1CA2CA12CA9GAA | |
| SCHEMBL3898684 | 0.84 | CA12 (0.53) | CA1CA2CA12CA9CYP2D6 | |
| SCHEMBL7401274 | 0.84 | CA12 (0.55) | CA1CA2CA12CA9PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3604281-A1 | 2(1H)-QUINOLINONE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-2566872-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2566872-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8741884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2566872-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120093767-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20120093767-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| WO-2011139513-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139513-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093767-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | CA1 4446/4885CA2 4355/4885CA12 1886/4885 |
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TOP2A, TOP2B, TOP1 | CA1 4064/4885CA2 1393/4885CA12 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.